-
公开(公告)号:US20070185125A1
公开(公告)日:2007-08-09
申请号:US11510126
申请日:2006-08-25
申请人: Jean-Damien Charrier , Sharn Ramaya , Steven Durrant , Juan-Miguel Jimenez , Julian Golec , Michael Mortimore
发明人: Jean-Damien Charrier , Sharn Ramaya , Steven Durrant , Juan-Miguel Jimenez , Julian Golec , Michael Mortimore
IPC分类号: A61K31/497 , A61K31/496 , A61K31/4745 , A61K31/506 , A61K31/444 , C07D403/14 , C07D401/02
CPC分类号: C07D401/04 , C07D213/64 , C07D213/74 , C07D401/14 , C07D471/04
摘要: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
摘要翻译: 本发明涉及可用作蛋白激酶抑制剂的化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病,病症或病症的方法。 本发明还提供制备本发明化合物的方法。
-
公开(公告)号:US08304414B2
公开(公告)日:2012-11-06
申请号:US12109598
申请日:2008-04-25
IPC分类号: A61K31/50 , A61K31/501 , C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00
CPC分类号: C07D403/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D493/04 , C07D495/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula III: wherein Z1, Z2, and Z3 are as described in the specification; Q is —S—, —O—, —N(R4)—, or —CH(R6)—; R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式III的新型吡唑化合物:其中Z1,Z2和Z3如说明书所述; Q是-S - , - O - , - N(R4) - 或-CH(R6) - ; R1是T环D,其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R2和R2'如说明书所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为Aurora-2和GSK-3的抑制剂用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病。
-
公开(公告)号:US20100256170A1
公开(公告)日:2010-10-07
申请号:US12651639
申请日:2010-01-04
申请人: David Bebbington , Hayley Binch , Ronald Knegtel , Julian Golec , Sanjay Patel , Jean-Damien Charrier , David Kay , Robert Davies , Pan Li , Marion Wannamaker , Cornelia Forster , Albert Pierce
发明人: David Bebbington , Hayley Binch , Ronald Knegtel , Julian Golec , Sanjay Patel , Jean-Damien Charrier , David Kay , Robert Davies , Pan Li , Marion Wannamaker , Cornelia Forster , Albert Pierce
IPC分类号: A61K31/519 , C07D487/04 , A61P35/00 , A61P25/18 , A61P3/10
CPC分类号: C07D401/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D491/10 , C07D493/04 , C07D495/04 , C07D498/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式IV的新型吡唑化合物:其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R x和R y独立地选自T-R 3,或与它们的插入原子一起形成具有1-3个选自氧,硫或氮的环杂原子的稠合的,不饱和的或部分不饱和的5-8元环; R2,R2',T和R3如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病的极光-2和GSK-3的抑制剂。
-
公开(公告)号:US20070270444A1
公开(公告)日:2007-11-22
申请号:US11369220
申请日:2006-03-06
申请人: David Bebbington , Hayley Binch , Ronald Knegtel , Julian Golec , Sanjay Patel , Jean-Damien Charrier , David Kay , Robert Davies , Pan Li , Marion Wannamaker , Cornelia Forster , Albert Pierce
发明人: David Bebbington , Hayley Binch , Ronald Knegtel , Julian Golec , Sanjay Patel , Jean-Damien Charrier , David Kay , Robert Davies , Pan Li , Marion Wannamaker , Cornelia Forster , Albert Pierce
IPC分类号: A61K31/519 , A61K31/505 , A61P35/00 , A61P7/12 , A61P9/00 , C07D401/00 , C07D471/00
CPC分类号: C07D401/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D491/10 , C07D493/04 , C07D495/04 , C07D498/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式IV的新型吡唑化合物:其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R“X”和“R”独立地选自TR 3,或者与它们的插入原子一起形成稠合的,不饱和的或部分不饱和的, 具有1-3个选自氧,硫或氮的环杂原子的5-8元环; 和R 2,R 2,R 3和R 3如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病的极光-2和GSK-3的抑制剂。
-
公开(公告)号:US20070179133A1
公开(公告)日:2007-08-02
申请号:US11504528
申请日:2006-08-15
申请人: David Bebbington , Hayley Binch , Jean-Damien Charrier , Simon Everitt , Julian Golec , David Kay , Ronald Knegtel , Andrew Miller , Francoise Pierard
发明人: David Bebbington , Hayley Binch , Jean-Damien Charrier , Simon Everitt , Julian Golec , David Kay , Ronald Knegtel , Andrew Miller , Francoise Pierard
IPC分类号: A61K31/541 , A61K31/5377 , A61K31/53 , C07D417/02 , C07D413/02 , C07D403/02
CPC分类号: C07D403/12
摘要: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
摘要翻译: 本发明涉及可用于蛋白激酶抑制剂的化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病,病症或病症的方法。
-
公开(公告)号:US20050004110A1
公开(公告)日:2005-01-06
申请号:US09952878
申请日:2001-09-14
申请人: David Bebbington , Hayley Binch , Ronald Knegtel , Julian Golec , Sanjay Patel , Jean- Damien Charrier , David Kay , Robert Davies
发明人: David Bebbington , Hayley Binch , Ronald Knegtel , Julian Golec , Sanjay Patel , Jean- Damien Charrier , David Kay , Robert Davies
IPC分类号: C07D403/12 , A61K31/415 , A61K31/437 , A61K31/4709 , A61K31/4725 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K45/00 , A61P1/16 , A61P3/08 , A61P3/10 , A61P3/14 , A61P5/00 , A61P9/00 , A61P9/10 , A61P11/06 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/10 , A61P25/18 , A61P25/28 , A61P29/00 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D239/26 , C07D239/36 , C07D239/70 , C07D239/88 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D475/10 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D491/052 , C07D491/107 , C07D491/113 , C07D491/20 , C07D493/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D521/00 , C07
CPC分类号: C07D401/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D493/04 , C07D495/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered carbocyclo ring; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式III的新型吡唑化合物:其中环D是选自芳基,杂芳基,杂环基或碳环基的5-7元单环或8-10元双环; R x和R y与它们的插入原子一起形成稠合的,不饱和的或部分不饱和的5-8元碳环; 和R 2和R 2'如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病的极光-2和GSK-3的抑制剂。
-
公开(公告)号:US20070190634A1
公开(公告)日:2007-08-16
申请号:US11786150
申请日:2007-04-11
申请人: David Bebbington , Hayley Binch , Jean-Damien Charrier , Simon Everitt , Julian Golec , David Kay , Ronald Knegtel , Andrew Miller , Francoise Pierard
发明人: David Bebbington , Hayley Binch , Jean-Damien Charrier , Simon Everitt , Julian Golec , David Kay , Ronald Knegtel , Andrew Miller , Francoise Pierard
IPC分类号: C02F3/34
CPC分类号: C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
摘要: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
摘要翻译: 本发明涉及可用作蛋白激酶抑制剂的化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病,病症或病症的方法。
-
公开(公告)号:US06664247B2
公开(公告)日:2003-12-16
申请号:US10025164
申请日:2001-12-19
IPC分类号: A61K3133
CPC分类号: C07D403/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D493/04 , C07D495/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula IIIa: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx, Ry, R2, and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式IIIa的新型吡唑化合物:其中R 1是T环D,其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R x,R y,R 2和R 2'如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为Aurora-2和GSK-3的抑制剂用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病。
-
公开(公告)号:US06653300B2
公开(公告)日:2003-11-25
申请号:US10026975
申请日:2001-12-19
申请人: David Bebbington , Jean-Damien Charrier , Julian Golec , Jeremy Green , David Kay , Ronald Knegtel , Andrew Miller , Ronald Tomlison , Pan Li
发明人: David Bebbington , Jean-Damien Charrier , Julian Golec , Jeremy Green , David Kay , Ronald Knegtel , Andrew Miller , Ronald Tomlison , Pan Li
IPC分类号: A61K3133
CPC分类号: C07D403/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D493/04 , C07D495/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula I′: wherein Q′ is —O—, —C(R6′)2—, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclopropanediyl, and R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T—R3 or L—Z—R3, or Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式I'的新型吡唑化合物:其中Q'是-O - , - C(R 6')2,1,2-环丙烷二基,1,2-环丁烷二基或1,3-环丙烷二基, 并且R 1是T环D,其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R x和R y独立地选自TR 3或LZR 3,或R x和R y与它们的插入原子一起形成稠合的,不饱和的或部分不饱和的, 具有0-3个杂原子的5-7元环; 和R 2和R 2'如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为Aurora-2和GSK-3的抑制剂用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病。
-
公开(公告)号:US07625913B2
公开(公告)日:2009-12-01
申请号:US10026992
申请日:2001-12-19
IPC分类号: C07D403/12 , A61K31/506
CPC分类号: C07D403/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D493/04 , C07D495/04 , C07D513/04
摘要: This invention describes novel pyrazole compounds of formula IIIc: wherein R1 is T—Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx, Ry, R2, and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译: 本发明描述了式IIIc的新型吡唑化合物:其中R1是T环D,其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; Rx,Ry,R2和R2'如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为Aurora-2和GSK-3的抑制剂用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病。
-
-
-
-
-
-
-
-
-